Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase--further experimental evidence for a multisite model.

@article{Garrigos1997CompetitiveAN,
  title={Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase--further experimental evidence for a multisite model.},
  author={Manuel Garrigos and Lluis M. Mir and St{\'e}phane Orlowski},
  journal={European journal of biochemistry},
  year={1997},
  volume={244 2},
  pages={
          664-73
        }
}
P-glycoprotein, a plasma membrane protein overexpressed in multidrug-resistant (MDR) cells, exhibits in vitro an ATPase activity and is responsible for the energy-dependent efflux of structurally unrelated cytotoxic drugs (like vinblastine) and various MDR-reversing agents (like verapamil and progesterone) from these MDR cells. To investigate the mechanism of P-glycoprotein interaction with various compounds, we measured the P-glycoprotein ATPase activity on membrane vesicles prepared from the… 
Bromocriptine modulates P-glycoprotein function.
TLDR
The effects of BCT on P-GP function can be linked to a specific interaction with P-gp, probably involving inhibition of P- gp-mediated drug transport.
P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.
TLDR
In the present review, the relations between glucosylceramide synthase activity, Pregnane X receptor and development of P-gp mediated MDR phenotype are discussed, with attention focused on the changes in protein kinase systems that are associated with the development of M DR phenotype.
The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane
TLDR
P-gp-mediated cholesterol redistribution in the cell membrane makes it likely that P-gp contributes in stabilizing the cholesterol-rich microdomains, rafts and caveolae, and that it is involved in the regulation of cholesterol trafficking in cells.
The equilibrium and kinetic drug binding properties of the mouse P-gp1a and P-gp1b P-glycoproteins are similar
TLDR
The mouse isoforms do not appear to exhibit functional differences at the level of initial substrate interaction with protein, suggesting an unlikely role as a physiological substrate.
Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: evidence for half-of-the-sites reactivity.
TLDR
The data support the mechanistic proposal that substrate binding at one putative transport binding site precludes activity at another unequal site; many of the substrates examined exert a negative allosteric effect on the other transport site (and vice versa).
Multidrug resistance P-glycoprotein is not involved in cholesterol esterification.
TLDR
It is concluded that the esterification of cholesterol is not correlated with MDR1 or MRP1 activity, thus excluding their role in the intracellular transport of endocytosis-derived cholesterol.
Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities.
TLDR
It is shown that P-glycoprotein contains two distinct sites for drug binding and transport, and that, unexpectedly, these sites interact in a positively cooperative manner, suggesting a two-site model may be fundamental to multidrug transport by P- glycoprotein.
Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship.
  • A. Lespine, Solenne Martin, M. Alvinerie
  • Biology, Chemistry
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2007
Characterization of two pharmacophores on the multidrug transporter P-glycoprotein.
TLDR
The molecular characteristics involved in the binding selectivity of P-glycoprotein are investigated by means of a molecular modeling approach using various substrates combined with an enzymological study using these substrates and native membrane vesicles prepared from MDR cells.
...
...

References

SHOWING 1-10 OF 44 REFERENCES
ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells.
TLDR
It is confirmed that multidrug-resistant cells express an energy-dependent plasma membrane transporter for hydrophobic drugs, and a system for the detailed biochemical analysis of this transport process is established.
The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate.
TLDR
Evidence is obtained that verapamil is actively transported by the MDR-related P-glycoprotein and that verAPamil and daunorubicin are non-competing substrates for P- glycoprotein.
Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators.
TLDR
The results lead to the conclusion that these steroids, although sharing related structures, have distinct modulating sites on P-gp, and their mutually non-exclusive interactions when mixed induce a synergistic modulation of P-GP ATPase activity.
Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement.
TLDR
Analysis of the effect of calcium channel blockers and Ca2+ ion on the VCR binding to K562/ADM plasma membrane indicates that Ca2- ion is not required for theVCR binding and that verapamil competitively inhibits the V CR binding without concerning Ca2+.
Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.
TLDR
Results suggest that verapamil enhances antitumor agent retention through competition for closely related binding sites on P-glycoprotein.
...
...